BioSpace News Archive

Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™) preclinical programs will be presented as an e-poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place from June 22-24, 2020.

Teva Canada to be first company to import emergency supply of salbutamol inhalers - providing access to critically needed medication for Canadian patients

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer.

Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a $53 million Series C extension, which brings the Series C round to over $90 million.

New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.

U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above

Siren, a medical device company that has developed breakthrough technology to embed microsensors within fabric, allowing for mass production of affordable, washable smart textiles with remote patient monitoring applications, announced the appointment of David Castiglioni as Chief Commercial Officer.

Cochlear received FDA approval to lower the age of implantation at the beginning of COVID-19 crisis; earlier access to cochlear implantation for children provides opportunity for better hearing, speech and language outcomes in children born deaf

Dr. Sundy brings deep expertise in translational medicine and innovative drug development from leadership role at Gilead

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it will hold a call for investors and the NPC community on Wednesday, May 20, 2020 at 4:30 pm EDT. “We look forward to speaking to the patient and investor communities about the data from our comp